Drugs / Carotuximab
Trials 28
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 16 trials | ||||||
| Phase 1 | NCT05401110 | Sep 2023 → Jan 2028 expected | non-small cell lung carcinoma | Karen Reckamp, MD, MS | Recruiting | No outcome recorded |
| Phase 1 | NCT03181308 | Nov 2017 → Jul 2019 | non-small cell lung carcinoma | Tracon Pharmaceuticals Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02429843 | Nov 2015 → Dec 2018 | lung cancer | University of Alabama at Birmingham | Completed | No outcome recorded |
| Phase 1 | NCT03780010 | Sep 2015 → Jun 2019 | non-small cell lung carcinoma | Tracon Pharmaceuticals Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01332721 | Apr 2011 → Sep 2012 | — | Tracon Pharmaceuticals Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00582985 | Dec 2007 → Jun 2011 | cancer, metastatic neoplasm | Tracon Pharmaceuticals Inc. | Completed | No outcome recorded |
| Phase 1/29 trials · 1 missed | ||||||
| Phase 1/2 | NCT02560779 | Nov 2016 → Aug 2019 | hepatocellular carcinoma | Tracon Pharmaceuticals Inc. | Completed | No outcome recorded |
| Phase 1/2 | NCT02555306 | Sep 2015 → Aug 2017 | age-related macular degeneration | Santen Inc. | Completed | No outcome recorded |
| Phase 1/2 | NCT02520063 | Feb 2015 → Dec 2022 | breast cancer | University of Alabama at Birmingham | Completed | No outcome recorded |
| Phase 1/2 | NCT01975519 | Dec 2013 → Mar 2019 | soft tissue sarcoma | Tracon Pharmaceuticals Inc. | Completed | No outcome recorded |
| Phase 1/2 | NCT01806064 | Mar 2013 → Dec 2018 | renal cell carcinoma | Tracon Pharmaceuticals Inc. | Terminated | No outcome recorded |
| Phase 1/2 | NCT01648348 | Nov 2012 → May 2016 | adult glioblastoma, anaplastic astrocytoma, anaplastic oligodendroglioma, giant cell glioblastoma +1 | National Cancer Institute (NCI) | Completed | Missed primary |
| Phase 1/2 | NCT01326481 | Jun 2011 → Sep 2014 | breast cancer | Tracon Pharmaceuticals Inc. | Completed | No outcome recorded |
| Phase 1/2 | NCT01306058 | Feb 2011 → Jun 2016 | hepatocellular adenoma, hepatocellular carcinoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1/2 | NCT01090765 | Feb 2010 → Apr 2014 | castration-resistant prostate carcinoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 211 trials · 1 missed | ||||||
| Phase 2 | NCT05534646 | Dec 2023 → Jan 2028 expected | castration-resistant prostate carcinoma | Edwin Posadas, MD | Recruiting | No outcome recorded |
| Phase 2 | NCT03418324 | Mar 2018 → Nov 2019 | prostate cancer | Cedars-Sinai Medical Center | Completed | No outcome recorded |
| Phase 2 | NCT03211234 | Jul 2017 → Dec 2019 | age-related macular degeneration | Santen Inc. | Completed | No outcome recorded |
| Phase 2 | NCT02664961 | Mar 2016 → Apr 2018 | epithelioid trophoblastic tumor, placental site trophoblastic tumor | Tracon Pharmaceuticals Inc. | Terminated | No outcome recorded |
| Phase 2 | NCT02396511 | Jan 2015 → Dec 2017 | choriocarcinoma | Tracon Pharmaceuticals Inc. | Completed | No outcome recorded |
| Phase 2 | NCT01778530 | Dec 2012 → Feb 2014 | glioblastoma | National Cancer Institute (NCI) | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT01727089 | Nov 2012 → Aug 2017 | clear cell renal carcinoma, papillary renal cell carcinoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2 | NCT01564914 | May 2012 → Jun 2015 | glioblastoma | Tracon Pharmaceuticals Inc. | Completed | No outcome recorded |
| Phase 2 | NCT01381861 | Jul 2011 → Aug 2012 | fallopian tube carcinoma, ovarian cancer, primary peritoneal carcinoma | Tracon Pharmaceuticals Inc. | Completed | No outcome recorded |
| Phase 2 | NCT01375569 | Jun 2011 → Feb 2014 | hepatocellular carcinoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2 | NCT01328574 | Mar 2011 → May 2014 | ureter cancer, urothelial carcinoma | National Cancer Institute (NCI) | Completed | Missed primary |
| Phase 31 trial · 1 missed | ||||||
| Phase 3 | NCT02979899 | Feb 2017 → Apr 2019 | angiosarcoma | Tracon Pharmaceuticals Inc. | Completed | Missed primary |
| Phase not stated1 trial | ||||||
| — | NCT02354612 | — | cancer | Tracon Pharmaceuticals Inc. | No longer available | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 29 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Carotuximab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05534646 ↗ |
| Known as | c-SN6j | ChEMBL registry synonym — accepted as the source's own label CHEMBL2109321 ↗ |
| Known as | DE-122 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02555306 ↗ |
| Known as | TRC105 | “TRC105 is a chimeric anti-angiogenic monoclonal antibody that binds cluster of differentiation 105 (CD105), a transmembrane receptor selectively expressed by proliferating...” NCT01306058 ↗21“Carotuximab (TRC105) and Sorafenib” NCT02560779 ↗ |
| Action | Inhibit | “thus inhibiting angiogenesis and tumor growth” NCT01090765 ↗1“Endoglin inhibitor” CHEMBL2109321 ↗ |
| Modality | Monoclonal antibody | “TRC105 is a human/murine chimeric immunoglobulin heavy constant gamma 1 (IgG1) kappa monoclonal antibody” NCT01090765 ↗ |
| Route | Intravenous | “Intravenous infusion at 1 mg/kg every 2 weeks” NCT01090765 ↗ |
| Target | ENG | “Endoglin inhibitor” CHEMBL2109321 ↗ |